<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00636285</url>
  </required_header>
  <id_info>
    <org_study_id>MAB-A001</org_study_id>
    <nct_id>NCT00636285</nct_id>
  </id_info>
  <brief_title>Safety and Pharmacokinetics Study in Adults for the Prevention of S. Epidermidis Infection in Low Birth Weight Infants</brief_title>
  <official_title>Phase 1, Open-Label, Dose-Ranging, Safety and Pharmacokinetics Study in Adults of BSYX-A110, a Human Chimeric Anti-Staphylococcal Monoclonal Antibody for the Prevention of S. Epidermidis Infection in Low Birth Weight Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biosynexus Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biosynexus Incorporated</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this Phase 1 study is to evaluate the safety and pharmacokinetics of BSYX-A110
      in a small number of healthy adult volunteers. Following the demonstration of safety in
      adults, this anti-Staphylococcal monoclonal antibody will then be evaluated in the target
      population of hospitalized low birth weight neonates.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will evaluate the safety of three doses of BSYX-A110 in adults before initiating
      studies in the target population of low birth weight infants. This will be an open label,
      dose-ranging study of BSYX-A110 in 12 adults. The dose levels to be evaluated are 3, 10 and
      20 mg/kg. Each dose level will enroll 4 adult volunteers who will receive one dose of
      BSYX-A110 intravenously. The primary endpoint of this study is safety and tolerability. The
      secondary endpoints include the pharmacokinetics of the rise in anti-LTA antibody and opsonic
      activity against S. epidermidis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2001</start_date>
  <completion_date type="Actual">November 2001</completion_date>
  <primary_completion_date type="Actual">September 2001</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the safety and tolerability.</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the serum levels (pharmacokinetics) of anti-LTA antibodies (ELISA; the functional opsonic activity against S. epidermidis; and correlate the levels of anti-LTA antibodies achieved with opsonic activity against S. epidermidis</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Staphylococcal Sepsis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BSYX-A110, Dosed intravenously, 3mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BSYX-A110, Dosed intravenously, 10mg/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Pagibaximab</other_name>
    <other_name>BSYX-A110</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BSYX-A110</intervention_name>
    <description>BSYX-A110, Dosed intravenously, 3 mg/kg</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Pagibaximab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BSYX-A110</intervention_name>
    <description>BSYX-A110, Dosed intravenously, 10 mg/kg</description>
    <arm_group_label>3</arm_group_label>
    <other_name>Pagibaximab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects must be 18 years of age or older.

          2. Subjects must in good general health, without significant medical history, physical
             examination findings or clinical laboratory abnormalities.

          3. Negative screening pre-treatment pregnancy test for female subjects.

          4. Subjects of childbearing potential must agree to use an acceptable method of
             contraception throughout the course of the study.

          5. All aspects of the protocol explained and written informed consent obtained.

        Exclusion Criteria:

          1. Known or suspected immunodeficiency (e.g. HIV infection, significant risk factors for
             HIV, primary immunosuppressive disorder), use of immunosuppressive or antineoplastic
             drugs except corticosteroids used for indications other than immunosuppression.

          2. Clinically significant laboratory abnormality (greater than 1.5 upper limit of
             normal.).

          3. Serology positive for HIV, hepatitis B surface antigen or hepatitis C antibody.

          4. History of leukemia, lymphoma or other malignancy.

          5. Clinically significant cardiac, respiratory, renal, hepatic, neurological disorder

          6. Pregnant or lactating females (women of childbearing potential will undergo a
             pregnancy test).

          7. Receipt of any vaccine within 30 days.

          8. History of drug or alcohol dependence, or significant acute or chronic medical or
             psychiatric illness which would limit the subject's ability to complete the study
             and/or compromise the objectives of the study.

          9. Fever or acute illness within 3 days prior to treatment. (These subjects can be
             rescheduled for treatment at a later date).

         10. Participation in another investigational drug or vaccine trial within 30 days.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leonard Weisman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.biosynexus.com</url>
    <description>Biosynexus Incorporated</description>
  </link>
  <verification_date>October 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 27, 2008</study_first_submitted>
  <study_first_submitted_qc>March 7, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 14, 2008</study_first_posted>
  <last_update_submitted>October 8, 2008</last_update_submitted>
  <last_update_submitted_qc>October 8, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 9, 2008</last_update_posted>
  <responsible_party>
    <name_title>Gerald Fischer, MD, President and CEO</name_title>
    <organization>Biosynexus Incorporated</organization>
  </responsible_party>
  <keyword>A110</keyword>
  <keyword>Safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Birth Weight</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

